PAK1 inhibitor NVS‐PAK1‐1 inhibits degeneration of synaptic spines in cultured neurons exposed to amyloid or tau and in 5XFAD mice following oral administration

These data support the hypothesis that inhibition of PAK1 confers dendritic spine resilience against Aβ and tau oligomers in early-stage preclinical models. Ongoing oncology clinical trials assessing effects of PAK1 inhibitors point to the possibility of testing PAK1 inhibitor approaches in AD trials.